- Home
- VTVT vs OTLK Comparison
VTVT vs OTLK Comparison
Compare VTVT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- OTLK
- Stock Information
- Founded
- VTVT 2015
- OTLK 2010
- Country
- VTVT United States
- OTLK United States
- Employees
- VTVT N/A
- OTLK N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTVT Health Care
- OTLK Health Care
- Exchange
- VTVT Nasdaq
- OTLK Nasdaq
- Market Cap
- VTVT 38.8M
- OTLK 33.6M
- IPO Year
- VTVT 2015
- OTLK 2016
- Fundamental
- Price
- VTVT $14.05
- OTLK $2.23
- Analyst Decision
- VTVT Strong Buy
- OTLK Strong Buy
- Analyst Count
- VTVT 1
- OTLK 6
- Target Price
- VTVT $35.00
- OTLK $23.08
- AVG Volume (30 Days)
- VTVT 8.5K
- OTLK 1.2M
- Earning Date
- VTVT 03-12-2025
- OTLK 02-12-2025
- Dividend Yield
- VTVT N/A
- OTLK N/A
- EPS Growth
- VTVT N/A
- OTLK N/A
- EPS
- VTVT N/A
- OTLK N/A
- Revenue
- VTVT $1,000,000.00
- OTLK N/A
- Revenue This Year
- VTVT N/A
- OTLK N/A
- Revenue Next Year
- VTVT N/A
- OTLK $603.93
- P/E Ratio
- VTVT N/A
- OTLK N/A
- Revenue Growth
- VTVT 11011.11
- OTLK N/A
- 52 Week Low
- VTVT $7.38
- OTLK $0.87
- 52 Week High
- VTVT $30.99
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- VTVT 46.82
- OTLK 48.26
- Support Level
- VTVT $13.90
- OTLK $2.08
- Resistance Level
- VTVT $14.35
- OTLK $2.31
- Average True Range (ATR)
- VTVT 0.58
- OTLK 0.28
- MACD
- VTVT 0.03
- OTLK 0.12
- Stochastic Oscillator
- VTVT 42.61
- OTLK 60.54
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.